SEC investigating Illumina over acquisition of cancer test developer Grail

  • 📰 CNBC
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 72%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Last month, the SEC informed Illumina about the probe and requested documents and communications related to the. The agency also asked for statements and disclosures about the "conduct and compensation" of certain members of both Illumina and Grail's management, according to the filing.

Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

 /  🏆 12. in NL
 

Bedankt voor uw reactie. Uw reactie wordt na beoordeling gepubliceerd.

Nederland Laatste Nieuws, Nederland Headlines